Clinical Trial

Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer

Study acronym: PIPAC-NAL-IRI
Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated July 13, 2026 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
The PIPAC NAL-IRI study is designed to examine the maximal tolerated dose of nanoliposomal irinotecan (Nal-IRI, Onivyde) administered with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC), in a monocentric, phase I trial.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-03-11; most recent amendment 2026-07-10.
Status change: Recruiting → Active, Not Recruiting 2026-07-10
Status change: Not Yet Recruiting → Recruiting 2022-12-28
Trial Details
NCT Number NCT05277766
Lead Sponsor University Hospital, Ghent
Collaborators: Kom Op Tegen Kanker, University Ghent
Conditions Peritoneal Carcinomatosis, Peritoneal Metastases, Colorectal Cancer, Small Bowel Cancer, Appendix Cancer, Gastric Cancer, Pancreatic Cancer, Bile Duct Cancer
Enrollment 45 participants
Start Date 2022-11-21
Primary Completion 2026-08-01 (estimated)
Study Completion 2027-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-13